Expert Opinion on Drug Discovery最新文献

How do drug discovery scientists address the unmet need of long COVID syndrome therapeutics and what more can be done? 药物发现科学家如何解决长期COVID综合征治疗的未满足需求？还可以做些什么？

IF 6 2区医学

Expert Opinion on Drug Discovery Pub Date : 2025-07-16 DOI: 10.1080/17460441.2025.2534056

Pasquale Pagliano, Flora Salzano, Chiara D'Amore, Annamaria Spera, Valeria Conti, Veronica Folliero, Gianluigi Franci, Tiziana Ascione

{"title":"How do drug discovery scientists address the unmet need of long COVID syndrome therapeutics and what more can be done?","authors":"Pasquale Pagliano, Flora Salzano, Chiara D'Amore, Annamaria Spera, Valeria Conti, Veronica Folliero, Gianluigi Franci, Tiziana Ascione","doi":"10.1080/17460441.2025.2534056","DOIUrl":"10.1080/17460441.2025.2534056","url":null,"abstract":"Introduction: Long COVID (LC), also known as post-acute COVID-19 syndrome (PASC), has emerged as a significant public health concern characterized by persistent symptoms following SARS-CoV-2 infection. This condition affects regardless of initial illness severity and can significantly impair daily functioning. Understanding the implications of LC is crucial, given that approximately 6.9 % of adults reported related symptoms in 2022, with increased prevalence among women and individuals of Hispanic descent. The pathogenesis of LC is multifactorial, involving mechanisms such as endothelial dysfunction, chronic inflammation, immune dysregulation, and potential viral persistence. The clinical manifestations include fatigue, cognitive impairment, musculoskeletal pain, and sleep disturbances. Current research emphasizes the importance of early antiviral interventions and vaccines to mitigate the risk of developing LC. Despite promising therapies like anti-inflammatory agents and metabolic enhancers, the lack of established biomarkers complicates diagnosis and treatment.Areas covered: The authors provide an overview of the pathogenesis of LC and briefly review the currently available therapy. The authors then give their perspectives on how best future drug discovery efforts can be utilized to address the current demand for novel LC therapeutics to reduce the burden of this public health problem.Expert opinion: Progress has been made in understanding the pathophysiology and potential treatment options, as well as in establishing reliable biomarkers for potential tailored strategies. Future research should prioritize both pharmacological and non-pharmacological interventions to enhance patient outcomes and quality of life. Addressing these challenges is essential for developing comprehensive care protocols for individuals affected by LC.","PeriodicalId":12267,"journal":{"name":"Expert Opinion on Drug Discovery","volume":" ","pages":"1-15"},"PeriodicalIF":6.0,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144636644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel insights into structure-activity relationships of kynurenine 3-monooxygenase inhibitors (KMOis) with emphasis on chemical space, activity landscape exploration. 犬尿氨酸3-单加氧酶抑制剂（KMOis）结构-活性关系的新见解，重点是化学空间，活性景观探索。

IF 6 2区医学

Expert Opinion on Drug Discovery Pub Date : 2025-07-16 DOI: 10.1080/17460441.2025.2532688

Chaitali Mallick, Sagnik Banerjee, Sk Abdul Amin

{"title":"Novel insights into structure-activity relationships of kynurenine 3-monooxygenase inhibitors (KMOis) with emphasis on chemical space, activity landscape exploration.","authors":"Chaitali Mallick, Sagnik Banerjee, Sk Abdul Amin","doi":"10.1080/17460441.2025.2532688","DOIUrl":"https://doi.org/10.1080/17460441.2025.2532688","url":null,"abstract":"Introduction: Kynurenine 3-monooxygenase (KMO) is a pivotal target in the kynurenine pathway (KP). KMO inhibitors (KMOis) decrease neurotoxic metabolites like 3-hydroxykynurenine and quinolinic acid while increasing neuroprotective kynurenic acid levels. It offers a promising therapeutic approach for treating neurodegenerative diseases, psychiatric disorders, acute pancreatitis, and immune-mediated conditions.Areas covered: The authors provide an overview of the biology and function of KMO and highlight the key evidence for KMOi design. The authors also provide a summary of the structure - activity relationships (SARs) of several series of KMOis based on a comprehensive search of literature utilizing PubMed, Google Scholar, and Scopus, covering the period between 2015 and 2025. This works also provides explicit coverage to the chemical space of human KMOis (hKMOis), thereby providing a novel framework for the rational design of next-generation therapeutics targeting this enzyme.Expert opinion: The KP, particularly KMO, has emerged as a compelling target for drug discovery. The Structure-Similarity Activity Trailing (SimilACTrail) map of hKMOis has provided novel insights for mapping the molecular landscape of hKMOis. A high scaffold-hopping rate (40.24%) underscores the potential for chemical innovation, while the identification of activity cliffs (0.58%) provides critical data for refining SARs. These findings offer a promising avenue for therapeutic development, with opportunities for the optimization of chemical scaffolds.","PeriodicalId":12267,"journal":{"name":"Expert Opinion on Drug Discovery","volume":" ","pages":"1-13"},"PeriodicalIF":6.0,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144642189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Designing drugs against leishmaniasis: is targeting the sterol biosynthesis pathway the answer? 设计抗利什曼病药物：靶向甾醇生物合成途径是答案吗？

IF 6 2区医学

Expert Opinion on Drug Discovery Pub Date : 2025-07-12 DOI: 10.1080/17460441.2025.2530589

Gonzalo Visbal, Maribel Navarro

{"title":"Designing drugs against leishmaniasis: is targeting the sterol biosynthesis pathway the answer?","authors":"Gonzalo Visbal, Maribel Navarro","doi":"10.1080/17460441.2025.2530589","DOIUrl":"https://doi.org/10.1080/17460441.2025.2530589","url":null,"abstract":"Introduction: Leishmaniasis is a devastating and complex parasitic disease caused by different species of protozoan members of the genus Leishmania. Unfortunately, available drugs are far from ideal and no vaccines are available. Under these circumstances, new effective antileishmanial drugs with reduced host toxicity and improved dosing protocols are urgently needed. The sterol biosynthesis pathway (SBP) is a promising focus for combating Leishmania infections. Thus, various strategies have been documented, such as drug repurposing, combined therapy, rational drug design, and the use of synergistic effects to develop the metallodrugs that can act on essential parasite targets.Areas covered: This article reviews the critical enzymes participating in the ergostane-based sterol biosynthesis pathway (SBP) of Leishmania species, as well as recent progress in rational drug design, repurposing drugs, combined therapies, and the development of metallodrugs for use as antileishmanial agents. This review is based on literature searchers using SciFinder, Lens.org, Google Scholar, Web of Science, Pub Med, and DrugBank.Expert opinion: The limited focus on human leishmaniasis has resulted in a shortfall in effective treatments for this parasitic disease. The post-squalene segment of the sterol biosynthetic pathway is a promising target for treating Leishmania infections, particularly effective drugs or metallodrugs that inhibit the CYP51 or 24-SMT enzymes.","PeriodicalId":12267,"journal":{"name":"Expert Opinion on Drug Discovery","volume":" ","pages":"1-14"},"PeriodicalIF":6.0,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144616854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Understanding the key challenges in tuberculosis drug discovery: what does the future hold? 了解结核病药物发现的主要挑战：未来会怎样？

IF 6 2区医学

Expert Opinion on Drug Discovery Pub Date : 2025-07-12 DOI: 10.1080/17460441.2025.2531229

Rima Zein-Eddine, Masoud Ramuz, Guislaine Refrégier, Johannes F Lutzeyer, Alexey Aleksandrov, Hannu Myllykallio

{"title":"Understanding the key challenges in tuberculosis drug discovery: what does the future hold?","authors":"Rima Zein-Eddine, Masoud Ramuz, Guislaine Refrégier, Johannes F Lutzeyer, Alexey Aleksandrov, Hannu Myllykallio","doi":"10.1080/17460441.2025.2531229","DOIUrl":"https://doi.org/10.1080/17460441.2025.2531229","url":null,"abstract":"Introduction: Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains a major global health concern. It spreads through airborne droplets and has a high mortality rate, particularly without treatment. Drug resistance is rising, with treatments against multidrug-resistant TB (MDR-TB) showing poor treatment success rates. The thick, lipid-rich wall of Mtb and its slow growth reduce antibiotic effectiveness, requiring long treatment courses of 4-6 months. Current therapies often fail against drug-resistant strains, highlighting the urgent need for new, short-course treatment, affordable, and combination-friendly drugs.Areas covered: Within this perspective, the authors review and comment on the following topics regarding Mtb resistance emergence and treatment strategies: i) Existing treatment ii) Resistance evolution in Mtb; iii) Key challenges in drug discovery targeting Mtb; iv) emerging strategies and recent advances in Mtb drug discovery, and v) Next-generation approaches. Literature was identified through a search of PubMed, google scholar, and web of science, from January 2010 to March 2025.Expert opinion: AI is accelerating the discovery of bioavailable and safe preclinical drug candidates for TB, though data limitations and biological complexity remain challenging. Future progress requires multi-modal models, open-access datasets, and interdisciplinary collaboration.","PeriodicalId":12267,"journal":{"name":"Expert Opinion on Drug Discovery","volume":" ","pages":"1-16"},"PeriodicalIF":6.0,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144616856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

From bench to bedside: the development journey of fruquintinib as a colorectal cancer therapy. 从实验室到临床：fruquininib作为结直肠癌治疗药物的发展历程。

IF 6 2区医学

Expert Opinion on Drug Discovery Pub Date : 2025-07-11 DOI: 10.1080/17460441.2025.2530597

María San-Román-Gil, Lucrezia Zumstein, Arianna Zappi, Andrea Modrego-Sanchez, Beatriz Soldevilla, Rocío Garcia-Carbonero

{"title":"From bench to bedside: the development journey of fruquintinib as a colorectal cancer therapy.","authors":"María San-Román-Gil, Lucrezia Zumstein, Arianna Zappi, Andrea Modrego-Sanchez, Beatriz Soldevilla, Rocío Garcia-Carbonero","doi":"10.1080/17460441.2025.2530597","DOIUrl":"https://doi.org/10.1080/17460441.2025.2530597","url":null,"abstract":"Introduction: Fruquintinib is a novel oral tyrosine kinase inhibitor (TKI) with high selectivity for vascular endothelial growth factor receptors (VEGFR), which play a key role in tumor angiogenesis. Blocking this pathway represents an essential strategy in the continuum of care of patients with metastatic colorectal cancer (mCRC). Fruquintinib has been recently approved as monotherapy for refractory mCRC based on the FRESCO and FRESCO-2 pivotal trials, which demonstrated significant overall survival (OS) benefits compared to placebo, with manageable toxicity.Areas covered: This article summarizes the preclinical development, pharmacology, clinical safety, and efficacy of fruquintinib in refractory mCRC patients and discusses current and future research to optimize its use as monotherapy and in combination with other treatments and potentially expand its use to earlier treatment lines and other types of cancer. A literature search (Dec 2024) was conducted in MEDLINE and EMBASE, and abstracts from major oncology conferences (AACR, ASCO, and ESMO) were reviewed.Expert opinion: Fruquintinib expands the treatment armamentarium for patients with refractory mCRC, providing additional survival. Its high selectivity for VEGFR may minimize off-target effects, improving patients' safety and tolerability. Further research on combination strategies and biomarkers will be key to optimizing patient selection and broadening their clinical applications.","PeriodicalId":12267,"journal":{"name":"Expert Opinion on Drug Discovery","volume":" ","pages":"1-15"},"PeriodicalIF":6.0,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144616855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New opportunities and current challenges using animal models for the discovery of novel countermeasures for acute radiation syndrome. 利用动物模型发现急性辐射综合征新对策的新机遇和当前挑战。

IF 6 2区医学

Expert Opinion on Drug Discovery Pub Date : 2025-07-10 DOI: 10.1080/17460441.2025.2528966

Vijay K Singh, Thomas M Seed

{"title":"New opportunities and current challenges using animal models for the discovery of novel countermeasures for acute radiation syndrome.","authors":"Vijay K Singh, Thomas M Seed","doi":"10.1080/17460441.2025.2528966","DOIUrl":"10.1080/17460441.2025.2528966","url":null,"abstract":"Introduction: The availability of well-characterized small and large animal models is critical for the discovery and development of new drugs that counter the negative health effects of unwanted, acute ionizing radiation exposures.Area covered: This article discusses the opportunities and challenges of small and large animal models for the development and regulatory approval of novel drugs for acute radiation syndrome (ARS). Various animal models of ARS have been analyzed for both strengths and weaknesses relative to the development of drugs for ARS following the Food and Drug Administration (FDA) Animal Rule. This article is based on a search of literature utilizing PubMed, covering the period up to March 2025.Expert opinion: Relative to large animal models, the rhesus macaque model is currently the most used and best characterized for translational relevance. Other large animal models (e.g. minipig) are currently used as well to evaluate other specific types of acute injury, such as cutaneous injuries. Due to the limited supply of rhesus macaques for studying radiation injury and countermeasure development, it is of some urgency to further characterize and consider the use of alternative models, especially large animal models, for advanced research and subsequent regulatory approval of ARS countering drugs.","PeriodicalId":12267,"journal":{"name":"Expert Opinion on Drug Discovery","volume":" ","pages":"1-16"},"PeriodicalIF":6.0,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144583502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Animal models of psoriasis for novel drug discovery: a literature update. 用于新药发现的牛皮癣动物模型：文献更新。

IF 6 2区医学

Expert Opinion on Drug Discovery Pub Date : 2025-07-09 DOI: 10.1080/17460441.2025.2528959

Zih-Chan Lin, Shih-Chun Yang, Thi Thu Phuong Tran, Jia-You Fang

{"title":"Animal models of psoriasis for novel drug discovery: a literature update.","authors":"Zih-Chan Lin, Shih-Chun Yang, Thi Thu Phuong Tran, Jia-You Fang","doi":"10.1080/17460441.2025.2528959","DOIUrl":"https://doi.org/10.1080/17460441.2025.2528959","url":null,"abstract":"Introduction: Psoriasis is a chronic, immune-mediated inflammatory skin disorder with a multifactorial pathogenesis involving keratinocyte proliferation, dysregulated immune responses, and vascular remodeling. The development of effective therapeutics mainly relies on preclinical models that can reproduce disease-relevant mechanisms.Areas covered: This review outlines current in vivo psoriasis models, including spontaneous mutation models, transgenic and knockout mice, xenotransplantation systems, and cytokine-induced and imiquimod-induced models. Each model is evaluated for its ability to replicate key histological and immunological features of human psoriasis, such as acanthosis, immune cell infiltration, and cytokine network activation. The utility of CRISPR/Cas9 gene editing in generating targeted models is also discussed, thus highlighting its potential use for mechanistic studies. Finally, this review also emphasizes the limitations in translational applicability and the need for multimodel validation strategies regarding psoriasis. This article was based on a comprehensive literature search using PubMed, Scopus, and Google Scholar databases, covering publications from January 2015 to March 2025.Expert opinion: Despite extensive model development, no single system fully mimics human psoriatic disease. The imiquimod-induced model remains widely used due to its practicality, although it better reflects acute inflammation compared with chronic pathology. The combination of complementary models and the incorporation of human-derived tissues or immune components may improve translational relevance. Advances in genome editing and humanized systems are likely to shape the future of psoriasis research and therapeutic discovery.","PeriodicalId":12267,"journal":{"name":"Expert Opinion on Drug Discovery","volume":" ","pages":"1-16"},"PeriodicalIF":6.0,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144590813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Discovery of novel cathepsin K inhibitors for osteoporosis treatment using a deep learning-based strategy. 使用基于深度学习的策略发现用于骨质疏松症治疗的新型组织蛋白酶K抑制剂。

IF 6 2区医学

Expert Opinion on Drug Discovery Pub Date : 2025-07-02 DOI: 10.1080/17460441.2025.2527686

Qi Li, Xue-Chun Han, Si-Rui Zhou, Yu Lu, Yu-Ji Wang, Jin-Kui Yang

{"title":"Discovery of novel cathepsin K inhibitors for osteoporosis treatment using a deep learning-based strategy.","authors":"Qi Li, Xue-Chun Han, Si-Rui Zhou, Yu Lu, Yu-Ji Wang, Jin-Kui Yang","doi":"10.1080/17460441.2025.2527686","DOIUrl":"https://doi.org/10.1080/17460441.2025.2527686","url":null,"abstract":"Background: Cathepsin K (CTSK), a cysteine protease of the papain family, exhibits high expression in activated osteoclasts, making it a key therapeutic target for osteoporosis. However, there are currently no CTSK inhibitors available for clinical use.Research design and methods: The authors employed a combination of deep learning approaches and experimental methods to identify novel CTSK inhibitors. Firstly, the authors utilized Chemprop to develop a predictive model for predicting CTSK inhibition. Subsequently, the top 100 predicted molecules were selected for experimental validation, with the most potent inhibitors chosen for further analysis, including enzyme kinetics, molecular docking, molecular dynamics simulations, and RANKL-induced osteoclastogenesis assays.Results: The authors identified six compounds exhibiting concentration-dependent CTSK inhibitory effects, with Quercetin, γ-Linolenic acid (GLA), and Benzyl isothiocyanate (BITC) demonstrating the highest potency. Enzyme kinetics studies revealed that these inhibitors employ distinct mechanisms of CTSK inhibition. Molecular dynamics simulations further showed that Quercetin and BITC form stable interactions at the CTSK active site. Moreover, in-vitro studies demonstrated that Quercetin and GLA significantly inhibit RANKL-induced osteoclastogenesis in RAW264.7 cells.Conclusions: This study led to the development of a deep learning model capable of predicting CTSK inhibitors and identified Quercetin, GLA, and BITC as promising candidates for the treatment of osteoporosis.","PeriodicalId":12267,"journal":{"name":"Expert Opinion on Drug Discovery","volume":" ","pages":"1-12"},"PeriodicalIF":6.0,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144539754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Preclinical models of insomnia: advances, limitations, and future directions for drug discovery. 失眠的临床前模型：进展、局限性和药物发现的未来方向。

IF 6 2区医学

Expert Opinion on Drug Discovery Pub Date : 2025-07-02 DOI: 10.1080/17460441.2025.2528135

Oscar Arias-Carrión

{"title":"Preclinical models of insomnia: advances, limitations, and future directions for drug discovery.","authors":"Oscar Arias-Carrión","doi":"10.1080/17460441.2025.2528135","DOIUrl":"10.1080/17460441.2025.2528135","url":null,"abstract":"Introduction: Insomnia is a highly prevalent and clinically burdensome disorder that profoundly affects cognition, emotional regulation, cardiometabolic health, and neurodegenerative progression. Despite advances in understanding its neurobiology, current animal models fail to capture the chronic, heterogeneous, and comorbid nature of human insomnia, impeding progress in translational drug discovery.Areas covered: This narrative review critically appraises genetic, environmental, pharmacological, and circuit-level models of insomnia, focusing on their translational relevance to drug discovery and is based on literature searches using PubMed and Scopus (2000-2025) where key systematic reviews were identified. The author also discusses how oversimplified paradigms and limited modeling of comorbidity constrain clinical applicability and highlight emerging tools - optogenetics, chemogenetics, CRISPR, wearable EEG, and AI - that enable high-resolution mapping of sleep - wake mechanisms.Expert opinion: A paradigm shift toward integrated, multidimensional models is urgently needed to reflect the complexity of chronic insomnia better. Embedding these models into translational pipelines - through precision genetics, circuit manipulation, and AI-enhanced analytics - will accelerate mechanism-based drug discovery and support the development of durable, personalized treatments for this disabling and multifactorial disorder.","PeriodicalId":12267,"journal":{"name":"Expert Opinion on Drug Discovery","volume":" ","pages":"1-14"},"PeriodicalIF":6.0,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144527108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The potential of academic drug discovery: successes and challenges. 学术药物发现的潜力：成功与挑战。

IF 6 2区医学

Expert Opinion on Drug Discovery Pub Date : 2025-07-02 DOI: 10.1080/17460441.2025.2528125

Matthew Stremlau, Barbara S Slusher

引用次数: 0